AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

INTERNATIONAL BIOTECHNOLOGY TST PLC

Board/Management Information Nov 20, 2023

5163_bfr_2023-11-20_b9b98820-47f4-4836-a291-493d2d0f425f.html

Board/Management Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3995T

Intl. Biotechnology Trust PLC

20 November 2023

20 November 2023

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

("IBT" or the "Company")

Update on Fund Management arrangements and related services

Further to the Company's previous announcements, the Board is pleased to report that with effect from 20 November 2023:

·      Schroder Unit Trusts Limited ("SUTL") has been appointed as the Company's Fund Manager and Alternative Investment Fund Manager ("AIFM").

·      Ailsa Craig and Marek Poszepczynski have joined Schroder Investment Management Limited ("SIML", a sister company to SUTL) from SV Health Partners LLP and will continue as the Company's portfolio managers.

·      The Depositary agreement with Northern Trust Company has been terminated and the Company's new Depositary will be HSBC Bank plc.

·      The Company's website is www.schroders.com/IBT.

·      SIML has been appointed as Company Secretary and can be contacted at [email protected].

·      The registered office address of the Company is set to change to 1 London Wall Place, London EC2Y 5AU.

For further information, please contact:

Fund Manager - SUTL

Augustine Chipungu      +44 (0) 20 7658 2106

Corporate Broker - Deutsche Numis

Nathan Brown                +44 (0)20 7260 1426 / +44 (0)7795 964 870

Financial PR - KL Communications

Charles Gorman            +44 (0)20 3995 6673 / +44 (0) 7795 977 967

LEI: 213800N1QUJ744P76D11

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDGPGQUGUPWGUC

Talk to a Data Expert

Have a question? We'll get back to you promptly.